Results 81 to 90 of about 107,795 (308)

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

Cancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai, Tao Fan, Chu Xiao, Ziqin Deng, Yixiao Liu, Chunxiang Li, Jie He   +6 more
wiley   +1 more source

The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. [PDF]

, 1989
B. I. Lord, Miguel H. Bronchud, Shuzi Owens, James Chang, Anthony Howell, L Souza, T. M. Dexter   +6 more
openalex   +1 more source

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high‐risk, HER2‐negative breast cancer: An open‐label, randomized controlled trial

Cancer Communications, EarlyView.
Abstract Background The standard adjuvant chemotherapy for early‐stage, high‐risk breast cancer includes anthracyclines and taxanes. While anthracycline‐based regimens have proven effective in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, their efficacy may be reduced in HER2‐negative patients due to the lack of co ...
Yu Song, Yingjiao Wang, Xi Cao, Ying Xu, Yidong Zhou, Qiang Sun, Songjie Shen   +6 more
wiley   +1 more source

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients is withheld from effective chemo(immunotherapy).
Nikki de Rouw, Leila‐Sophie Otten, Mart P. Kicken, Berber Piet, Bonne Biesma, Bianca van Veggel, Christi M.J. Steendam, Ben van den Borne, Lizza E.L. Hendriks, Sander Croes, Anne‐Marie C. Dingemans, Daphne W. Dumoulin, Ron H.J. Mathijssen, Jacobus A. Burgers, Alwin D.R. Huitema, Hieronymus J. Derijks, Maarten J. Deenen, Michel M. van den Heuvel, Rob ter Heine   +18 more
wiley   +1 more source

Human recombinant granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities. [PDF]

, 1988
SG Emerson, Y C Yang, Steven C. Clark, Michael W. Long   +3 more
openalex   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

Characterization of the cell surface receptor for human granulocyte/macrophage colony-stimulating factor. [PDF]

, 1986
L S Park, Della Friend, Steven Gillis, David L. Urdal   +3 more
openalex   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Granulocyte-macrophage colony-stimulating and binding activities of purified human urinary colony-stimulating factor to murine and human bone marrow cells [PDF]

, 1982
K Motoyoshi, Toshio Suda, Kazuhiro Kusumoto, Fumimaro Takaku, Y Miura   +4 more
openalex   +1 more source

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source